BioSpace News Archive

Plus Therapeutics, Inc. announced that the World Health Organization’s International Non-proprietary Name Expert Committee has selected the non-proprietary name “Rhenium obisbemeda” for the Company’s lead investigational targeted radiotherapeutic, formerly known as 186RNL.

BIOCORP announces the signature of a partnership agreement with Novo Nordisk for the commercialization of Mallya, initially in Japan.

EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the company will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held October 26-28, 2022 in Amsterdam, the Netherlands.

Boston Scientific Corporation generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported basis, 13.7 percent on an operational1 basis and 11.5 percent on an organic2 basis, all compared to the prior year period.

NovaBay® Pharmaceuticals, Inc. announces the newest addition to the DERMAdoctor® Picture Porefect® collection: 15% Niacinamide Pore Minimizing Serum.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments.

Time BioVentures today announced the close of its first fund, Time ked by an A-List roster of biotech and healthcare luminaries, the fund will finance game-changing innovations in medicine.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced a live webcast on Wednesday, November 9th at 11:30 a.m. Eastern Time to discuss its financial results for the third quarter of 2022.

Positive high-level results from the CAPItello-291 Phase III trial showed that AstraZeneca’s capivasertib in combination with FASLODEX.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2022.